Lexaria Bioscience Corp. (LEXX)

3.1300 +0.1300 (+4.33%) At close: 04:00PM EDT

Lexaria Bioscience Corp.

740 McCurdy Road
Suite 100
Kelowna, BC V1X 2P7
Canada
250 765 6424
https://lexariabioscience.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 5

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Christopher A. Bunka	Chairman & CEO	291.19k	N/A	1962
Mr. John M. Docherty M.Sc.	President & Director	290.46k	N/A	1969
Mr. Nelson D. Cabatuan CPA	Chief Financial Officer	N/A	N/A	1979
Kristin Hamilton	Director of Operations	N/A	N/A	N/A
Vanessa Carle	Head of Legal	N/A	N/A	N/A
Dr. Philip N. Ainslie Ph.D.	Advisor & Consultant	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Corporate governance

Lexaria Bioscience Corp.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.